3.8 Article

Can acetazolamide be used to treat diseases involving increased bone mineral density?

Journal

INTRACTABLE & RARE DISEASES RESEARCH
Volume 5, Issue 4, Pages 284-289

Publisher

INT RESEARCH & COOPERATION ASSOC BIO & SOCIO-SCIENCES ADVANCEMENT
DOI: 10.5582/irdr.2016.01067

Keywords

Acetazolamide; osteopetrosis; carbonic anhydrase inhibitor; craniometaphyseal dysplasia; osteochondrodysplasia; sclerosing bone dysplasia

Ask authors/readers for more resources

Sclerosing bone dysplasias are a series of clinically and genetically heterogeneous diseases characterized by functional failure of the osteoclasts in bone resorption, leading to an excessive amount of bone mineral density (BMD) which could have serious clinical consequences. We treated three children affected with seriously high levels of BMD with acetazolamide, with the intention of inducing metabolic acidosis, thus increasing bone resorption and reducing BMD. All our patients tolerated and followed the treatment well and the clinical response was satisfactory in all cases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available